Hikma Pharmaceuticals is in the midst of a shift in its research and development strategy that will prioritize fewer but higher-value products over a larger number of drugs that represent smaller-scale opportunities, per a Q&A at this year’s Jefferies Healthcare Conference in London in late November.
Attended by Hikma’s chief executive officer Riad Mishlawi and the company’s chief financial officer Khalid Nabilsi, the Q&A session provided...